Opportunity Costs of Surgical Resection and Perioperative Chemotherapy for Locoregional Pancreatic Adenocarcinoma.
Szu-Aun LimScarlett B HaoBreana A BoydAnastasios T MitsakosWilliam IrishAidan M BurkeAlexander A ParikhRebecca A SnyderPublished in: JCO oncology practice (2021)
Patients with locoregional pancreatic cancer spend a considerable percentage of their survival time in receipt of oncologic care. Further research to determine predictors of increased time burden is warranted to better inform shared decision making.